Relapsed biliary tract cancer, and ASCO, beckon.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
Golcadomide and iberdomide are set to feature at EHA.
A Libtayo combo fails to beat Keytruda in first-line melanoma.
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Rival BTK degraders face off in CLL patients naive to BTK inhibition.
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
